OverviewSuggest Edit

Vapotherm develops and manufactures comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. The Company is an inventor of  inventor of Hi-VNI® Technology.

TypePublic
Founded1999
HQExeter, NH, US
Websitevapotherm.com
Employee Ratings4.5

Latest Updates

Employees (est.) (Dec 2019)279(+2%)
Job Openings14
Revenue (FY, 2019)$48.1 M(+36%)
Share Price (Dec 2020)$27.2 (+3%)
Cybersecurity ratingBMore

Key People/Management at Vapotherm

Joseph Army

Joseph Army

President & Chief Executive Officer
John Landry

John Landry

Vice President & Chief Financial Officer
Lindsay Becker

Lindsay Becker

Vice President, Human Resources
David Blouin

David Blouin

Vice President, U.S. Sales
John Coolidge

John Coolidge

Vice President, Operations
Jill Dooling

Jill Dooling

Vice President, Strategic Accounts
Show more

Vapotherm Office Locations

Vapotherm has an office in Exeter
Exeter, NH, US (HQ)
100 Domain Dr
Show all (1)

Vapotherm Financials and Metrics

Vapotherm Revenue

Embed Graph
View revenue for all periods
Vapotherm's revenue was reported to be $48.10 m in FY, 2019
USD

Revenue (Q3, 2020)

30.6m

Gross profit (Q3, 2020)

15.5m

Gross profit margin (Q3, 2020), %

50.8%

Net income (Q3, 2020)

(12.4m)

EBIT (Q3, 2020)

(11.2m)

Market capitalization (4-Dec-2020)

697.2m

Closing stock price (4-Dec-2020)

27.2

Cash (30-Sept-2020)

139.0m

EV

604.7m
Vapotherm's current market capitalization is $697.2 m.
Annual
USDFY, 2016FY, 2017FY, 2019

Revenue

30.1m35.6m48.1m

Revenue growth, %

18%

Cost of goods sold

20.2m22.4m26.8m

Gross profit

9.9m13.2m21.3m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

9.1m8.2m7.9m10.7m10.6m9.4m12.3m12.0m10.8m19.1m35.2m30.6m

Cost of goods sold

5.5m4.8m5.1m6.5m6.5m5.8m7.1m6.5m6.0m9.9m17.5m15.0m

Gross profit

3.6m3.4m2.8m4.2m4.1m3.6m5.2m5.5m4.8m9.2m17.6m15.5m

Gross profit Margin, %

40%41%35%40%39%39%42%46%44%48%50%51%
Annual
USDFY, 2016FY, 2017FY, 2019

Cash

5.8m26.5m71.7m

Accounts Receivable

5.9m7.0m8.2m

Prepaid Expenses

1.8m2.3m4.1m

Inventories

8.2m11.5m9.1m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

56.7m46.1m83.5m60.4m148.3m139.0m

Accounts Receivable

6.7m7.3m6.8m11.9m16.5m10.9m

Prepaid Expenses

2.5m2.3m2.1m4.0m4.5m4.9m

Inventories

12.4m11.2m10.8m9.1m18.6m25.0m
Annual
USDFY, 2016FY, 2017FY, 2019

Net Income

(31.0m)(23.1m)(51.1m)

Depreciation and Amortization

1.5m1.3m3.1m

Inventories

(3.3m)374.0k5.1m

Accounts Payable

285.0k996.0k98.0k
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(22.0m)(29.6m)(13.0m)(25.8m)(38.6m)(13.8m)(21.9m)(34.3m)

Depreciation and Amortization

1.1m1.6m621.0k1.4m2.2m1.1m2.1m3.4m

Inventories

(3.1m)(1.1m)1.8m3.0m3.4m(12.0k)(9.2m)(15.5m)

Accounts Payable

(127.0k)(336.0k)(1.7m)(1.6m)(1.6m)1.3m3.4m2.8m
USDFY, 2016

Financial Leverage

-0.3 x
Show all financial metrics

Vapotherm Operating Metrics

Q3, 2018

Hospitals Engaged

1.20 k
Show all operating metrics

Vapotherm Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Vapotherm Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Vapotherm Online and Social Media Presence

Embed Graph

Vapotherm Blogs

Use of High Velocity Nasal Insufflation in combination with servo controlled FiO2 delivery for the ambulation of a patient with severe Interstitial Lung Disease (ILD)

Thomas Hillmann, Respiratory Physiotherapist University of Essen, Ruhrlandklinik Vapotherm’s high velocity therapy is a tool for treating respiratory distress. Although individual results may vary, Vapotherm believes this case study is an example of the clinical benefit Vapotherm’s high velocity the…

Velocity – Ep 9 – Physicians discuss research on Mask-Free NIV for COPD patients

https://www.youtube.com/watch?v=rjoFMHPp3c4 Episode 9: Physicians discuss research on Mask-Free NIV for COPD patients In this episode, Dr. Kirk Hinkley interviews esteemed researcher and pulmonologist Dr. Charles Atwood about the latest research concerning use of high velocity therapy for COPD patie…

How are Hospitals and Respiratory Care Departments Reimbursed for Respiratory Care Services?

For most products, paying for a service or item is a simple transaction based on the listed price. The merchant posts the price, the consumer agrees, makes the payment, and gets the product. As healthcare providers, we are bombarded with the question: ‘Why can’t you operate like other businesses?’ T…

What Authority/Influence Do Respiratory Care Leaders Have with Regard to Productivity Measures and Benchmarking?

In talking with Respiratory Therapy leaders about productivity for more than a few years, their responses about their authority range from ‘none’ to ‘done’.  Those replying that they have no authority indicate that administration has chosen the metric to use for each department and there is no possi…

What is Benchmarking and How are Performance Metrics Used for Benchmarking in the Context of RT Department Productivity?

In a previous blog, I went into detail about various metrics and how to assess the validity of metrics when examining Respiratory Department Productivity. Here I’m going to review commonly used metrics in our hospitals and define each, discuss the validity of each, and  how to best capture and use t…

How are Respiratory Care Department Productivity Systems Captured and Tracked?

Having discussed the various performance metrics that are utilized in a previous blog, I’d like to discuss how these metrics are captured, tracked, and used within a Respiratory Care Department.   The following questions will be addressed in this blog:  Why metrics matter?  How to evaluate the valid…
Show more

Vapotherm Frequently Asked Questions

  • When was Vapotherm founded?

    Vapotherm was founded in 1999.

  • Who are Vapotherm key executives?

    Vapotherm's key executives are Joseph Army, John Landry and Lindsay Becker.

  • How many employees does Vapotherm have?

    Vapotherm has 279 employees.

  • What is Vapotherm revenue?

    Latest Vapotherm annual revenue is $48.1 m.

  • What is Vapotherm revenue per employee?

    Latest Vapotherm revenue per employee is $172.4 k.

  • Who are Vapotherm competitors?

    Competitors of Vapotherm include ALung Technologies, Getinge and Trimedyne.

  • Where is Vapotherm headquarters?

    Vapotherm headquarters is located at 100 Domain Dr, Exeter.

  • Where are Vapotherm offices?

    Vapotherm has an office in Exeter.

  • How many offices does Vapotherm have?

    Vapotherm has 1 office.